Alumis (ALMS) Income from Continuing Operations (2023 - 2026)
Alumis (ALMS) posted quarterly Income from Continuing Operations of 92892000.0 for Q4 2025, down 181.75% year-over-year from 113633468.39 in Q4 2024, and up 16.13% quarter-over-quarter from 110752000.0 in Q3 2025.
Powered by 
Analysis
Alumis (ALMS) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Income from Continuing Operations for 3 consecutive years, with 92892000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 181.75% year-over-year to 92892000.0; the TTM figure through Dec 2025 stood at 250942000.0 (down 8.38% YoY), while the FY2025 annual figure was 243286000.0, down 4.66% from the prior year.
- Income from Continuing Operations improved to 92892000.0 in Q4 2025 per ALMS's latest filing, from 110752000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 59321000.0 in Q2 2025 and bottomed at 110752000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 55004454.55 across 3 years, with a median of 48943000.0 in 2024.
- On a YoY basis, Income from Continuing Operations climbed as much as 204.98% in 2025 and fell as far as 181.75% in 2025.
- Alumis' Income from Continuing Operations stood at 41295000.0 in 2023, then climbed by 20.16% to 32970000.0 in 2024, then sank by 181.75% to 92892000.0 in 2025.
- Business Quant data shows ALMS's Income from Continuing Operations at 92892000.0 in Q4 2025, 110752000.0 in Q3 2025, and 59321000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alumis | 1.43 Bn | 924.11 Mn | - | -142.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -142.18 Mn |
| Dec 31, 2025 | -48.64 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.36 Mn |
| Mar 31, 2025 | -101.53 Mn |
| Dec 31, 2024 | -32.97 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -47.59 Mn |
| Dec 31, 2023 | -40.13 Mn |
| Sep 30, 2023 | -43.76 Mn |
| Jun 30, 2023 | -36.71 Mn |